07:45 AM EDT, 05/10/2024 (MT Newswires) -- Akero Therapeutics ( AKRO ) reported a Q1 net loss Friday of $0.90 per diluted share, wider than its loss of $0.55 per share a year earlier.

Analysts surveyed by Capital IQ expected a loss of $0.95.

As expected, no revenue for the quarter ended March 31 was reported.

As of March 31, Akero said it had $903.7 million in cash, cash equivalents, and short-term marketable securities, which it said should be enough to fund its phase 3 SYNCHRONY Histology and Real-World studies through their respective primary endpoints, as well as its current operating plan into H2 of 2027.